MANGOCEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $4.80M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Oct 19, 2023 | Before market open | – | – | – |
Press releases
Announcements Mangoceuticals filed with the SEC
Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Material agreement · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against
Regulation FD disclosure · EX-99.1 to Form 8-K
Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
Material agreement · Other events · EX-99.1 to Form 8-K
Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
Other events · EX-99.1 to Form 8-K
Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management
Other events · EX-99.1 to Form 8-K
Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Announces Formation of Strategy and Alternatives Committee
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Responds to and Refutes Recent Claims Made by Eli Lilly
Regulation FD disclosure · EX-99.1 to Form 8-K
INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Other events · EX-99.1 to Form 8-K
Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
Other events · EX-99.1 to Form 8-K
Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM,
Results of operations · EX-99.1 to Form 8-K
Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
Material agreement · Other events · EX-99.1 to Form 8-K
Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum
Listing notice · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
MangoRx with entrance into the non-Rx based, nutraceutical product space for sales on both direct-to-consumer online platforms and through
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of $1,200,000 Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Provides Update to Shareholders on Q3 Achievements and Guidance on Year End and Near-Term Initiatives
Results of operations · EX-99.1 to Form 8-K
Inc. Appoints Amanda Hammer as New Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K